Comparison of the Effectiveness of Baloxavir and Oseltamivir in Outpatients With Influenza B.
Takahiro TakazonoGenta ItoNaoki HosogayaNaoki IwanagaTakuji KomedaMasayuki KobayashiYoshitake KitanishiEriko OguraHiroshi MukaePublished in: Influenza and other respiratory viruses (2024)
This retrospective cohort study analyzed data from a Japanese health insurance database to assess the effectiveness of baloxavir (n = 4822) for preventing severe events compared with oseltamivir (n = 10,523) in patients with influenza B. The primary endpoint was hospitalization incidence (Days 2-14). The secondary endpoints included intravenous antibacterial drug use, pneumonia hospitalization, heart failure hospitalization, inhalational oxygen requirement, and use of other anti-influenza drugs. The hospitalization incidence was significantly lower with baloxavir (0.15% vs. 0.37%; risk ratio: 2.48, 95% confidence interval: 1.13-5.43). Pneumonia and additional anti-influenza therapy were also less frequent with baloxavir, thus supporting its use. Trial Registration: UMIN Clinical Trials Registry Study ID: UMIN000051382.
Keyphrases
- health insurance
- clinical trial
- heart failure
- randomized controlled trial
- systematic review
- risk factors
- study protocol
- phase ii
- affordable care act
- phase iii
- emergency department
- mesenchymal stem cells
- high dose
- drug induced
- atrial fibrillation
- big data
- open label
- adverse drug
- acute heart failure
- respiratory failure
- cell therapy
- data analysis
- essential oil